S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed
Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer
Sponsor: Cancer and Leukemia Group B
A PHASE3 clinical study on Colorectal Cancer, this trial is completed. The trial is conducted by Cancer and Leukemia Group B and has accumulated 8 data snapshots since 1994. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 1994
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- North Central Cancer Treatment Group
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Atlanta, United States, Bismarck, United States, Boston, United States, Buffalo, United States, Burlington, United States, Cedar Rapids, United States, Chapel Hill, United States, Chicago, United States, Cleveland, United States and 43 more location s